Non-small cell lung cancer (NSCLC), the most common (~ 85%) histological subtype of lung cancer, is characterized by various oncogenic mutations, such as those in KRAS (25%), EGFR (23%), PIK3CA (3%), BRAF (3%), MET (2%), and ERBB2 (1%); these mutations play a major role in driving cancer progression [1, 2]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.